A bout 500 000 noncardiac surgical procedures take place in Canada annually. 1 In the Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) study, myocardial injury after noncardiac surgery (MINS) (defined as a peak troponin T level ≥ 0.03 ng/mL due to myocardial ischemia) was the most frequent vascular complication (8%). 2 The crude 30-day mortality rate of MINS was 9.6%, and MINS was strongly associated with death. It may account for 34% of deaths within this period. 2 Because only a small minority of patients who experience MINS have symptoms, 2 most cases go undetected without systematic postoperative troponin T monitoring. Monitoring for MINS by means of perioperative troponin T levels may offer an opportunity to intervene and potentially reduce subsequent adverse events. Although the optimal treatment for MINS remains unclear, promising observational data suggest mortality advantages in patients given treatments after MINS and, thus, that MINS is likely modifiable. 3, 4 Moreover, in the VISION study, patients with MINS who died did so a mean of 9 days after their initial troponin T level elevation, which indicates that there is time to initiate treatment after MINS is detected. Perhaps as a consequence, Canadian 5 and international 6 guidelines recommend troponin monitoring after noncardiac surgery in patients at high cardiovascular risk.
The need to be judicial with resources requires consideration of both benefit and cost of any intervention. 7, 8 Information on the resource and health implications of routine troponin T monitoring after noncardiac surgery is limited. The goal of this initial, basic model was to estimate, using different postoperative troponin T monitoring strategies, the cost and health consequences resulting from routine troponin T monitoring in patients with various levels of preoperative MINS risk undergoing noncardiac surgery, with a focus on the detection of MINS (that is, without burdening the model with assumptions with regard to treatment effect).
Methods
The basis for these cost-consequence analyses was the VISION Study (clinicaltrials.gov, identifier NCT00512109). A previous report presents the details of enrolment and follow-up. 2 Since the VISION study did not measure resource use, this cost-consequence analysis was model-based.
Population
The VISION study enrolled patients aged 45 years or more who underwent noncardiac surgery that required an overnight hospital stay and who had general or regional anesthesia. This analysis includes all Canadian patients enrolled in the VISION study between September 2007 and October 2010 who had their troponin T level measured with the fourth-generation (non-high-sensitive) assay (Fig. 1) . We excluded patients who had an elevated troponin T level in the 7 days before surgery. The research ethics board at each site approved the protocol, and written informed consent was obtained from all patients.
Definition of myocardial injury after noncardiac surgery
We previously established the diagnostic criteria for MINS based on its prognostic impact on 30-day mortality. 2 Details on the adjudication procedure have been previously published; 2 in short, physicians evaluated extensive inhospital documentation of all patients with troponin elevation for ischemic features fulfilling the universal definition of myocardial infarction 6 and for alternative nonischemic causes for increased troponin levels (i.e., sepsis, pulmonary embolism and cardioversion). Using Cox regression, we analyzed the association between alternative diagnostic criteria for MINS and 30-day mortality after adjustment for preoperative characteristics and perioperative complications. Irrespective of the presence of ischemic symptoms or electrocardiographic changes, a peak troponin T level of 0.03 ng/mL or greater was independently associated with 30-day mortality (adjusted hazard ratio 3.87, 95% confidence interval 2.96-5.08). Therefore, MINS was defined as a troponin T value of 0.03 ng/mL or greater resulting from ischemia that occurs within 30 days after noncardiac surgery.
2 Differentiation between type 1 and type 2 infarction 6 was not attempted. For these analyses, we considered MINS events detected during the first 3 postoperative days (i.e., during the proposed troponin T monitoring period).
Model structure and computer simulation
We conducted a cost-consequence analysis from the perspective of the Canadian health care system. We measured the health consequences as the number of detected MINS events during the monitoring period. We expressed costs in 2015 Canadian dollars.
In our base-case model, we compared fourth-generation troponin T monitoring 6-12 hours after surgery and on postoperative days 1, 2 and 3 with standard care (i.e., reliance on suggestive myocardial ischemic symptoms to trigger evaluation for potential MINS). The troponin level was not systematically measured preoperatively.
The model was structured as a decision tree (Fig. 2) . It included the following health states: true-positive (detected MINS), true-negative (no MINS), false-negative (missed MINS) and false-positive. In the patients screened for elevation of the troponin T level, a false-positive health state was defined as troponin T elevation that was not due to myocardial ischemia (i.e., sepsis, pulmonary embolism or cardioversion). In the standard care alternative, falsepositive referred to patients primarily assessed because of symptoms suggestive of myocardial ischemia (e.g., chest pain) but deemed to be of noncardiac origin after further investigation.
The reference analysis was a probabilistic sensitivity analysis that calculated the mean cost and the mean number of detected events over 10 000 iterations generated by a second-order Monte Carlo simulation. We ran the model in Microsoft Excel spreadsheets with corresponding macros. We validated the model by extreme values and by the number of MINS cases estimated by the model against the primary data. Calibration of cost estimates was not possible because primary cost data were not available.
Data inputs
Data generated for 6021 Canadian VISION study patients informed the probabilities of the monitoring results. Since the VISION study did not include nonscreened patients, we estimated the number of detected and missed cases of MINS after standard care using the number of symptomatic MINS cases (assumed detected in standard care) and the number of asymptomatic MINS cases (assumed undetected in standard care). The VISION study did not collect information on clinical symptoms in patients without elevation of the troponin T level of 0.04 ng/mL or greater. We assumed the incidence of noncardiac chest pain (i.e., false-positive in the standard-care group) to be 1% and explored the impact of this assumption in sensitivity analysis. We opted for this very conservative estimate of false-positive health state to avoid any overestimation of the cost in the standard-care group. Table 1 summarizes the model parameters and their distributions.
The VISION study did not collect data on resource use except for coronary angiography. We estimated the cost of the 2 alternatives based on predefined diagnostic algorithms to confirm or exclude MINS in the case of elevated troponin T levels in screened patients or suggestive symptoms in the standard-care group. The algorithms included fourth-generation troponin T measurements as monitoring and as serial follow-up in the case of elevated troponin T or of clinical symptoms (triggered troponin T measurements), a cardiology consultation and follow-up visits, and serial electrocardiography and echocardiography for all patients with elevated troponin T levels. Canadian VISION data were the source for the probability of coronary angiography and for the probability that the troponin T level exceeded the upper limit of normal as late as on the last day of scheduled measurement, thus resulting in additional, triggered troponin T measurements in screened patients. The model did not include costs related to the noncardiac surgical procedure itself because these resource items were identical in the 2 alternatives. 12 Costs were inflated by the Canadian health care Consumer Price Index as necessary.
Sensitivity and scenario analyses
We explored the impact of the assumptions on resource use and costs resulting from the predefined diagnostic algorithms using sensitivity analyses. The worst-case scenario maximized the incremental costs of the monitoring program by assuming simultaneously a 25% cost increase in the screened patients and a 25% cost reduction for standard care. The best-case scenario reduced the incremental cost of the monitoring program by assuming the inverse.
We also assessed the impact of the assumption for all patients with elevated troponin T levels to undergo echocardiography by assuming that 50% and 75% of such patients would have echocardiography.
We assessed the impact of varying the false-positive rate in the standard-care patients (imputing 0% for sensitivity analyses and assuming 1% for the reference case). In the overall VISION population (i.e., not limited to Canadian centres), nonischemic causes for troponin elevation were adjudicated in 0.59% of patients (95/16 087), 2 as opposed to the 0.37% assumed in the current analysis (based on 22 cases of nonischemic troponin elevation in 6021 Can adian patients); therefore, we also ran a sensitivity analysis imputing 0.59% falsepositive in the monitoring alternative.
To assess the cost-effectiveness of troponin T monitoring in populations at various levels of risk for MINS, we analyzed the following subgroups: 1) age 65 years or more, 2) urgent/emergent surgery, 3) history of coronary artery disease and 4) age 65 years or more, or history of coronary artery disease, peripheral vascular disease, cerebrovascular event or diabetes.
Patients experience MINS at different times after the procedure. Therefore, varying timelines after the procedure and increasing numbers of troponin T measurements will detect events that had not yet occurred at the time of the previous measurement. This represents a major difference from screening programs for static disease (e.g., cancer), where a marginal approach is used for increasing the number of tests. To assess the impact of using different monitoring strategies, we estimated the cost and number of cases of MINS detected using monitoring based on 1) a single troponin T measurement 6-12 hours postoperatively, 2) measurements 6-12 hours postoperatively and on postoperative day 1, 3) measurements 6-12 hours postoperatively and on postoperative days 1 and 2, and 4) measurement only on postoperative days 1 and 2. In the base case, the troponin T level was measured 6-12 hours postoperatively and daily up to the third postoperative day (VISION study protocol). Table 2 shows the patients' demographic characteristics, preoperative risk factors, type of surgery. Table 3 summarizes the resources used in the various health states according to the diagnostic algorithms. The unit costs and their sources are shown in Table 2 .
Reference model
The incremental cost of a monitoring program consisting of 4 troponin T measurements was $112.18 per screened patient, including follow-up diagnostic tests and consultations in patients with elevated troponin T levels ( Table 4) . The incremental cost per additional case of MINS detected was $1632.51. The distribution of the simulations in the incremental cost-effectiveness plan is shown in supplementary Fig. S1 , Appendix 1 (available at canjsurg.ca/010217-a1). Under the assumption of 500 000 noncardiac surgical procedures per year in Canada, 1 the annual cost of a MINS monitoring program would amount to $56.1 million, with the incremental detection of 34 354 MINS events. The absolute 30-day mortality rate among patients with MINS was 9.6% (95% confidence interval 8.0-11.4). 2 
Sensitivity and scenario analyses
The incremental cost to detect an additional case of MINS rose to $2138 under the worst-case scenario and was $1134 in the best-case scenario. Table 5 shows the results of other sensitivity analyses.
The incremental cost per additional case detected was lower in patients at higher risk for MINS (Table 6 ; Supplementary Fig. 2, Appendix 1) .
Myocardial injury after noncardiac surgery occurred in 34.6% of patients within the first 6-12 hours after surgery, in 22.9% on the first postoperative day, in 26% on the *Except where noted otherwise. †Procedure performed within 72 hours of the surgery-triggering acute event. ‡Included thoracic aorta or aortoiliac reconstructive procedures, peripheral vascular reconstruction without aortic cross-clamping, extracranial cerebrovascular surgery and endovascular abdominal aortic aneurysm repair. §Included complex visceral resection, partial or total colectomy or stomach surgery, other intra-abdominal surgery, and major head and neck resection for tumour. ¶Included visceral resection (e.g., nephrectomy, ureterectomy, bladder resection, retroperitoneal tumour resection, radical procedure for cancer [i.e., exenteration], hysterectomy).
**Included major hip or pelvis surgery (hemi or total hip arthroplasty, internal fixation of hip, pelvic arthroplasty). † †Included craniotomy and spine surgery involving multiple levels of the spine. ‡ ‡Included parathyroid, thyroid, breast, hernia or local anorectal procedure, radical prostatectomy, transurethral prostatectomy, oopherectomy, salpingectomy, endometrial ablation, peripheral nerve surgery, ear/nose/throat surgery, vertebral disc surgery, spinal fusion, knee arthroplasty, hand surgery, cosmetic surgery, arteriovenous access surgery for dialysis, other surgery not fulfilling the major criteria as above. second postoperative day and in 16.5% on the third postoperative day. A monitoring protocol that measured the troponin T level 6-12 hours after surgery and daily on postoperative days 1, 2 and 3 resulted in the lowest incremental costs for detected MINS (Table 7) .
discussion
This analysis suggests that the incremental cost to avoid missing a MINS event through troponin T monitoring after noncardiac surgery in unselected patients aged 45 years or more would be less than $1650. The estimated incremental cost to detect an additional case of MINS was less than $1350 in selected populations (e.g., patients aged ≥ 65 yr, those undergoing urgent/emergent surgery and those with a history of cardiovascular disease). Among the screening protocols tested, monitoring consisting of troponin T measurements 6-12 hours after surgery and on postoperative days 1, 2, and 3 resulted in the lowest incremental costs per case of MINS detected. Under the assumption of an annual surgical volume of 500 000 inpatient noncardiac surgical procedures in Canada, 1 a budget of around $56 million would allow physicians to identify over 34 000 additional MINS cases.
Mantha and colleagues 13 evaluated the cost-effectiveness of a postoperative troponin T monitoring strategy to initiate heart rate control and surveillance in a coronary care unit after abdominal aortic aneurysm repair. They populated their model based on data from the literature and assumed a hypothetical relative risk of 0.55 for myocardial ischemia using the strategies mentioned. They concluded that troponin T monitoring after abdominal aortic aneurysm repair was cost-effective (US$12 641 per qualityadjusted life-year [QALY]).
Torborg and colleagues 14 conducted an economic analysis of perioperative troponin monitoring after noncardiac surgery in South Africa. They assumed a 25% reduction in 30-day rates of cardiovascular mortality and myocardial infarction after initiation of treatment with acetylsalicylic acid and statins in patients with positive screening results. The monitoring alternative dominated standard care, i.e., it prevented 30-day adverse events at lower cost.
Our model was populated by a large cohort of patients undergoing a broad spectrum of noncardiac surgical procedures, and it was limited neither by the use of QALY not specific for postoperative events nor by assumptions of a hypothetical treatment effect. In spite of these differences in methods, all evaluations suggest that there may be health gains achievable by troponin T monitoring after noncardiac surgery within commonly applied ceiling ratios. 
Strengths and limitations
Our study's strengths include the large, representative, contemporary sample of patients (> 6000, broad inclusion criteria) undergoing noncardiac surgery in Canada. In addition to assessing the cost per additional case of MINS detected, we also assessed affordability (i.e., the cost associated with a troponin T monitoring program). 15 Finally, the results are not limited by extensive assumptions regarding monitoring and treatment effect or by long-term extrapolations; rather, they rely closely on the observed data.
This cost-consequence analysis has limitations. The VISION study did not collect data on resource use. To estimate resource use in the presence of elevated troponin T levels, we applied diagnostic algorithms both for troponin T monitoring and for standard care, based on expert opinion that was not generated in a Delphi panel. We addressed this limitation by conducting scenario analyses that varied the cost of the monitoring and standard-care alternatives: even in the worst-case scenario, the incremental cost to detect an additional case of MINS remained moderate (< $2200).
Furthermore, given that the VISION study did not have a standard-care alternative, the model relied on the following assumptions with regard to the health states. First, we assumed that the proportion of MINS cases detected and missed by clinical assessment corresponded to the symptomatic and asymptomatic cases, respectively, of MINS. Second, because ischemic symptoms in patients with normal troponin T levels were not collected in the VISION study, we estimated the proportion of falsepositive findings (i.e., noncardiac chest pain) with standard care based on expert opinion. However, our sensitivity analyses suggest a limited impact of this parameter, and we opted for a conservative estimate of false-positive findings in the standard care alternative. As such, the results presented here underestimate the actual cost of standard care. In other words, the model overestimated the cost of troponin T monitoring after noncardiac surgery.
The source for estimation of coronary angiogram cost included both in-hospital and outpatient angiography. The model did not take into account whether coronary angiography in patients with MINS was performed during the hospital stay for noncardiac surgery or after discharge (plausible in the case of asymptomatic patients). However, coronary angiography was done in less than 1% of patients with MINS; as such, the impact on the overall cost of troponin T monitoring was minor. Furthermore, because more cases of MINS were detected with the troponin T monitoring alternative than with standard care, any potential impact of uncertainty with regard to angiography cost would have led to overestimation of the cost of troponin T monitoring.
Finally, the VISION study measured troponin T in all patients; thus, it did not provide estimates of the effect of troponin T monitoring on outcomes. There is no evidence from randomized controlled trials of the effectiveness of troponin T monitoring after noncardiac surgery on outcomes important to patients, and the optimal treatment of MINS has not been established. Therefore, we opted for a cost-consequence analysis with detected MINS as the health consequence of interest rather than assuming a treatment effect to estimate gain in survival or QALYs. However, this fact can also be considered as a strength because the model did not require extended assumptions or extrapolations. Furthermore, modelling guidelines 12, 16 agree that lack of data -in this case, evidence from randomized controlled trials to establish treatment for MINS -should not prevent economic evaluations. 16 A large randomized trial examining MINS treatment has recently been completed.
conclusion
More than 500 000 Canadians undergo inpatient noncardiac surgery annually, and around 40 000 patients will experience MINS, a condition strongly associated with 30-day mortality. The condition remains undetected in more than 4 in 5 patients (i.e., about 34 000 patients yearly in Canada) because of the lack of ischemic symptoms. Based on the estimated incremental cost per health gain, the implementation of a troponin T monitoring program after noncardiac surgery seems appealing. 
